CN111035658A - Use of pediococcus pentosaceus - Google Patents
Use of pediococcus pentosaceus Download PDFInfo
- Publication number
- CN111035658A CN111035658A CN201811196105.3A CN201811196105A CN111035658A CN 111035658 A CN111035658 A CN 111035658A CN 201811196105 A CN201811196105 A CN 201811196105A CN 111035658 A CN111035658 A CN 111035658A
- Authority
- CN
- China
- Prior art keywords
- pediococcus pentosaceus
- powder
- intestinal flora
- optionally
- pentosaceus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000191996 Pediococcus pentosaceus Species 0.000 title claims abstract description 115
- 230000000968 intestinal effect Effects 0.000 claims abstract description 55
- 230000001105 regulatory effect Effects 0.000 claims abstract description 11
- 238000004321 preservation Methods 0.000 claims abstract description 7
- 238000009629 microbiological culture Methods 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 32
- 241000894006 Bacteria Species 0.000 claims description 28
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 28
- 235000013618 yogurt Nutrition 0.000 claims description 23
- 230000009286 beneficial effect Effects 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 235000013325 dietary fiber Nutrition 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 241000589220 Acetobacter Species 0.000 claims description 5
- 241000606125 Bacteroides Species 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 5
- 241000588722 Escherichia Species 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 5
- 241000186866 Lactobacillus thermophilus Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 5
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 235000020247 cow milk Nutrition 0.000 claims description 4
- 235000010855 food raising agent Nutrition 0.000 claims description 4
- 230000002906 microbiologic effect Effects 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims 2
- 235000005911 diet Nutrition 0.000 abstract description 17
- 230000037213 diet Effects 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 10
- 235000013373 food additive Nutrition 0.000 abstract description 9
- 239000002778 food additive Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 9
- 241000699673 Mesocricetus auratus Species 0.000 description 25
- 230000036541 health Effects 0.000 description 16
- 239000006041 probiotic Substances 0.000 description 11
- 235000018291 probiotics Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002417 nutraceutical Substances 0.000 description 4
- 235000021436 nutraceutical agent Nutrition 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000288027 Chrysolophus pictus Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000835614 Pediococcus pentosaceus CGMCC 7049 Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/427—Pentosaceus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides application of pediococcus pentosaceus in preparation of a medicine, food, a food additive or a health-care product, wherein the medicine, the food additive or the health-care product is used for regulating intestinal flora, the pediococcus pentosaceus is preserved in the common microorganism center of China general microbiological culture Collection center (CGMCC) on 2015, 02 and 02 days, and the preservation number is CGMCC No. 10511. The pediococcus pentosaceus has an excellent function of regulating intestinal flora, is remarkably superior to medicaments, foods, food additives or health-care products prepared from the conventional commercial strain pediococcus pentosaceus JQI-7, and can effectively improve the symptom of intestinal flora imbalance caused by diet.
Description
Technical Field
The invention relates to the field of microorganisms, in particular to application of pediococcus pentosaceus, and more particularly to application of pediococcus pentosaceus in preparation of medicines, foods, food additives or health care products, application of pediococcus pentosaceus in regulation of intestinal flora, and application of pediococcus pentosaceus fermented yoghurt or pediococcus pentosaceus tablets in regulation of intestinal flora.
Background
The intestinal flora refers to microorganisms inhabiting in human intestinal tracts, and the intestinal flora is interdependent and restricted to form a dynamic balance system and interact with a host to influence the nutrition and health of organisms. Studies have shown that diet affects the structure of intestinal flora and its growth metabolism, for example, high fat diet affects the structure of intestinal flora, resulting in imbalance of intestinal flora, increased abundance of harmful bacteria, decreased abundance of beneficial bacteria, and health of host, which may induce chronic inflammatory reactions and metabolic syndrome, such as obesity, hyperlipidemia, diabetes, etc.
Probiotics refer to the general term for a class of microorganisms that live, through ingestion in sufficient quantities, to produce one or more specific and demonstrated functional health benefits to a host (WHO, 2011). At present, probiotics are widely applied to the fields of bioengineering, agriculture, food safety and life health, wherein the application of probiotic lactic acid bacteria is the most extensive.
The relationship between probiotics and intestinal flora is a great concern for researchers, because if a probiotic strain capable of significantly regulating intestinal flora can be found, the probiotic strain will have a profound influence on human life and health.
Disclosure of Invention
The present application is based on the discovery and recognition by the inventors of the following facts and problems:
pediococcus pentosaceus is used as an important probiotic lactic acid bacterium, and the prior Chinese patent application No. 201510941026.0 of Pediococcus pentosaceus JQI-7 and application thereof discloses the acid and bile salt resistance of a Pediococcus pentosaceus JQI-7(CGMCC No.10511) bacterium and the application of the bacterium in preparation of food or drugs for regulating blood fat, but whether the bacterium has a certain relation with intestinal flora or not, in other words, whether the bacterium can change or regulate the intestinal flora or not is also a problem of great interest to researchers. The inventor surprisingly finds that pediococcus pentosaceus JQI-7 has a very excellent function of regulating intestinal flora and is remarkably superior to the existing commercial strains, and supplementing pediococcus pentosaceus JQI-7 can very effectively improve the abundance of beneficial bacteria in intestinal tracts, reduce the abundance of harmful bacteria in intestinal tracts and further effectively improve the symptom of unbalanced intestinal flora caused by diet.
Therefore, in the first aspect of the invention, the invention provides the application of Pediococcus pentosaceus in preparing medicines, foods, food additives or health care products for regulating intestinal flora, wherein the Pediococcus pentosaceus is preserved in the general microbiological center of the China Committee for culture Collection of microorganisms at 02/2015, the preservation number is CGMCC No.10511, the preservation address is the microbial research institute of China academy of sciences, No. 3 of North West Lu No.1 Hotel, north Chengyang, Beijing, and the Pediococcus pentosaceus is classified and named as Pediococcus pentosaceus. For ease of description, this strain is referred to herein as Pediococcus pentosaceus JQI-7. The pediococcus pentosaceus disclosed by the embodiment of the invention has an excellent function of regulating intestinal flora, is remarkably superior to a medicine, food additive or health-care product prepared from the conventional commercial strain pediococcus pentosaceus JQI-7, and can effectively improve the symptom of intestinal flora imbalance caused by diet.
In a second aspect of the present invention, the present invention provides the use of pediococcus pentosaceus, deposited at the general microbiological culture collection center of the china committee for preservation of microorganisms at 2015 02/02 with the accession number of CGMCC No.10511, for the regulation of intestinal flora for non-diagnostic purposes, such as for scientific research or health care. The pediococcus pentosaceus provided by the embodiment of the invention has an excellent function of regulating intestinal flora, and is remarkably superior to the existing commercial strain, and the pediococcus pentosaceus JQI-7 can effectively improve the symptom of intestinal flora imbalance caused by diet.
According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:
according to an embodiment of the invention, said modulating the intestinal flora is performed by at least one of: increasing the abundance of beneficial bacteria in the gut; reducing the abundance of harmful bacteria in the intestinal tract. The inventor finds that the pediococcus pentosaceus of the embodiment of the invention or the medicine, food additive or health care product prepared from the pediococcus pentosaceus of the embodiment of the invention can effectively improve the abundance of beneficial bacteria in intestinal tracts, reduce the abundance of harmful bacteria in the intestinal tracts and further effectively improve the symptom of intestinal flora imbalance caused by diet.
According to an embodiment of the invention, the beneficial genera comprise at least one selected from the group consisting of acetobacter, bifidobacterium, lactobacillus. The inventor finds that the pediococcus pentosaceus according to the embodiment of the invention or the medicine, food additive or health product prepared from the pediococcus pentosaceus according to the embodiment of the invention has a remarkable effect of improving the abundance ratio of the beneficial bacteria.
According to an embodiment of the present invention, the harmful genus includes at least one selected from the group consisting of bacteroides, enterococcus, escherichia, and eurobacterium. The inventor finds that the pediococcus pentosaceus according to the embodiment of the invention or the medicine, food additive or health product prepared from the pediococcus pentosaceus according to the embodiment of the invention has a remarkable effect of reducing the abundance of the harmful bacteria.
In a third aspect of the invention, the invention provides the use of pediococcus pentosaceus fermented cow's milk or pediococcus pentosaceus tablets for regulating intestinal flora for non-diagnostic purposes, such as scientific research or health care, comprising pediococcus pentosaceus deposited at the common microorganism center of the china committee for the conservation of microbial cultures at 2015, 02/02 with a deposit number of CGMCC No. 10511. The inventor finds that the pediococcus pentosaceus fermented yoghurt or pediococcus pentosaceus tablet according to the embodiment of the invention can effectively improve the symptom of unbalanced intestinal flora caused by diet.
According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:
according to an embodiment of the invention, said modulating the intestinal flora is performed by at least one of: increasing the abundance of beneficial bacteria in the intestinal tract and reducing the abundance of harmful bacteria in the intestinal tract. The inventor finds that the pediococcus pentosaceus fermented yoghurt or pediococcus pentosaceus tablet provided by the embodiment of the invention can effectively improve the abundance of beneficial bacteria in intestinal tracts, reduce the abundance of harmful bacteria in the intestinal tracts and further effectively improve the symptom of intestinal flora imbalance caused by diet.
According to an embodiment of the invention, the beneficial genera comprise at least one selected from the group consisting of acetobacter, bifidobacterium, lactobacillus. The inventors found that the pediococcus pentosaceus fermented yoghurt or pediococcus pentosaceus tablets according to the embodiments of the present invention have a significant effect of improving the abundance of the above beneficial bacteria.
According to an embodiment of the present invention, the harmful genus includes at least one selected from the group consisting of bacteroides, enterococcus, escherichia, and eurobacterium. The inventors found that the pediococcus pentosaceus fermented cow's milk or pediococcus pentosaceus tablets according to the embodiments of the present invention have a significant effect of reducing the abundance of the above harmful bacteria.
According to the embodiment of the invention, the pediococcus pentosaceus fermented yoghurt is prepared from pediococcus pentosaceus powder, milk powder and a leavening agent.
According to an embodiment of the invention, the starter culture comprises lactobacillus bulgaricus powder and lactobacillus thermophilus powder. Furthermore, the pediococcus pentosaceus fermented yoghurt disclosed by the embodiment of the invention has better taste, higher nutritional value and easier preservation.
According to an embodiment of the present invention, the content of pediococcus pentosaceus in the pediococcus pentosaceus powder is 1.0 × 109CFU/g. According to the embodiment of the invention, the content of pediococcus pentosaceus in the pediococcus pentosaceus fermented yoghurt is high, so that the symptom of intestinal flora imbalance caused by diet can be further effectively improved.
According to an embodiment of the invention, the total weight of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4% based on the total weight of the pediococcus pentosaceus fermented yoghurt. The pediococcus pentosaceus fermented yoghurt disclosed by the embodiment of the invention has higher nutritional value, and can further effectively improve the symptom of intestinal flora imbalance caused by diet.
According to an embodiment of the invention, the total weight of the pediococcus pentosaceus powder is 1% based on the total weight of the pediococcus pentosaceus fermented yoghurt. According to the embodiment of the invention, the content of pediococcus pentosaceus in the pediococcus pentosaceus fermented yoghurt is high, so that the symptom of intestinal flora imbalance caused by diet can be further effectively improved.
According to the embodiment of the invention, the pediococcus pentosaceus fermented yoghurt is prepared by the following steps: 1) carrying out first mixing, homogenizing, sterilizing and first cooling treatment on the milk powder and water, wherein the sterilization is carried out for 300s at 121 ℃, and the temperature after the first cooling treatment is 42 ℃; 2) adding the activated leavening agent into the first cooling treatment product to perform fermentation treatment, wherein the fermentation treatment is performed for 10 hours at 42 ℃; 3) and carrying out second cooling treatment on the fermentation treatment product, and carrying out second mixing treatment on the second cooling treatment product and the pediococcus pentosaceus powder so as to obtain the pediococcus pentosaceus fermented yoghurt. The pediococcus pentosaceus fermented yoghurt prepared by the method has high nutritive value and high content and activity of the pediococcus pentosaceus, and can further effectively improve the symptom of intestinal flora imbalance caused by diet.
According to an embodiment of the invention, the pediococcus pentosaceus tablet comprises: freeze-dried powder of pediococcus pentosaceus, dietary fiber, sorbitol, and magnesium stearate. Furthermore, the pediococcus pentosaceus tablet according to the embodiment of the present invention is convenient to store and administer, and can further effectively improve the symptom of imbalance in intestinal flora caused by diet.
According to the embodiment of the invention, the content of the pediococcus pentosaceus in the pediococcus pentosaceus freeze-dried powder is 1.0 x 109CFU/g. According to the embodiment of the invention, the content of pediococcus pentosaceus in the pediococcus pentosaceus tablet is high, so that the symptom of intestinal flora imbalance caused by diet can be further effectively improved.
According to the embodiment of the invention, the freeze-dried powder of pediococcus pentosaceus is 25 parts by weight, the dietary fiber is 60 parts by weight, the sorbitol is 10 parts by weight, and the magnesium stearate is 5 parts by weight. The pediococcus pentosaceus tablet according to the embodiment of the invention is convenient to store and administer, and can further effectively improve the symptom of intestinal flora imbalance caused by diet.
Detailed Description
The following detailed description of embodiments of the invention is intended to be illustrative, and not to be construed as limiting the invention.
The technical problem to be solved by the application is to provide a new application of pediococcus pentosaceus JQI-7.
Disclosed is a food product prepared by fermentation of Pediococcus pentosaceus JQI-7. The food of the present invention is an edible product in any form in a broad sense, and examples thereof include yogurt, lactic acid bacteria beverage, lactic acid bacteria fermented bean product, cheese, processed food containing fermented yogurt, and health food.
The application also discloses a health-care product which contains the pediococcus pentosaceus JQI-7. In some embodiments, the nutraceutical of the present application is a live bacterial formulation for modulating the intestinal flora. The health care product can be various preparations of the active pediococcus pentosaceus JQI-7 alone, and can also be used together with other active ingredients as long as the activity is not influenced mutually; further, the health product preferably has a function complementation or promotion function between the active ingredients, for example, pediococcus pentosaceus JQI-7 can be combined with other probiotics to prepare a composite probiotic tablet, so as to achieve better or more active functions, and besides improving dyslipidemia and regulating intestinal flora, the health product can also have the functions of resisting inflammation, improving immunity and the like, and particularly, the health product can be determined according to the activity and the components of the composite probiotic tablet, and is not limited herein. In other embodiments, the nutraceutical further comprises a carrier or adjuvant acceptable in nutraceutical development. In the case of a live bacterial preparation, it is usually necessary to add a carrier or an auxiliary material, as long as there is no mutual inhibition or adverse side effect between the added carrier or auxiliary material and pediococcus pentosaceus JQI-7. The nutraceutical may be a tablet, capsule, oral liquid or powder, and in some embodiments, is a pediococcus pentosaceus tablet.
In one embodiment of the application, the pediococcus pentosaceus tablet comprises 25 weight parts of lyophilized powder of pediococcus pentosaceus JQI-7, 60 weight parts of dietary fiber, 10 weight parts of sorbitol and 5 weight parts of magnesium stearate, and the components are uniformly mixed and tableted to prepare the tablet.
The beneficial effect of this application lies in:
after a dyslipidemia and intestinal flora imbalance model is established through high-fat diet induction, the intervention of pediococcus pentosaceus JQI-7 can effectively improve hyperlipidemia symptoms caused by diet and effectively regulate intestinal flora imbalance caused by diet. The probiotic product prepared from pediococcus pentosaceus has a great development prospect in the aspect of assisting treatment of hyperlipidemia patients or adjusting intestinal flora.
The present invention is described in further detail below by way of specific examples.
Example 1
Culture and preparation of Pediococcus pentosaceus JQI-7 and LI05
1. Pediococcus pentosaceus JQI-7 was deposited in the general microbiological center of China Committee for culture Collection of microorganisms at 2.2.2015.2.the address of the deposition organization is the institute of microbiology, China academy of sciences, No. 3, North West Lu 1 institute of North West Lu, Chaoyang, Beijing, and the deposition number is CGMCC No. 10511. The pediococcus pentosaceus LI05 is purchased from China general microbiological culture Collection center with the preservation number of CGMCC No. 7049.
2. MRS culture medium: the beef cattle meat extract is prepared from casein peptone 10g/L, beef extract 10g/L, yeast extract 5g/L, glucose 20g/L, dipotassium hydrogen phosphate 2g/L, tween 801 g/L, triammonium citrate 2g/L, sodium acetate 5g/L, magnesium sulfate 0.1g/L and manganese sulfate 0.05g/L by adjusting pH to 6.5 and sterilizing at 121 ℃ for 20 min.
3. Taking out preserved Pediococcus pentosaceus JQI-7 or LI05, activating, inoculating to MRS liquid culture medium, culturing at 37 deg.C for 24 hr, centrifuging at 4 deg.C and 12000r/min for 15min, collecting bacterial sludge, adding appropriate amount of protectant, and freeze-drying at-80 deg.C for storage.
(II) preparation of gastric lavage reagent
Gavage reagent of drug control group: atorvastatin (blood fat reducing medicine) is prepared into 1mg/mL by using a proper amount of sterile water and is used as it is.
LI05 control group intragastric reagent: re-dissolving lyophilized powder of Pediococcus pentosaceus LI05 with appropriate amount of sterile water until viable count is 109CFU/mL, ready for use.
JQI-7 groups of intragastric agents: re-dissolving Pediococcus pentosaceus JQI-7 lyophilized powder with appropriate amount of sterile water until viable count is 109CFU/mL, ready for use.
(III) animal experiment verification
1. Establishing an animal model: after 50 male golden hamster 6-8 weeks old and 120g in weight are adaptively raised for one week, the golden hamster is randomly divided into five groups (n is 10), a normal group is fed with normal maintenance feed, a model group, a drug control group, an LI05 control group and a JQI-7 group are fed with high-fat feed, the blood lipid level of each golden hamster is detected after two-week high-fat feed induction, and golden hamsters of which the blood lipid level does not meet the standard are removed to ensure that the establishment of a hyperlipidemia model is successful, wherein the result is recorded as week 0.
2. Administration treatment: wherein the drug control group is administrated at a dose of 0.03mL/10g by intragastric administration, the LI05 control group and the JQI-7 group are administrated at a dose of 0.1mL/10g, the normal group and the model group are administrated with equal volume of sterile water, 1 time per day, and the intragastric administration is continued for eight weeks.
After the administration (recorded as 8 weeks), blood and feces samples of all groups of golden pheasants were collected, blood lipid levels were detected, bacterial genomic DNA in feces was extracted, and changes in intestinal flora of golden pheasants were determined by 16s DNA sequencing analysis.
(IV) conclusion of the experiment
Pediococcus pentosaceus JQI-7 can effectively regulate the unbalance of intestinal flora of hyperlipoidemia golden hamiltonii
After the model is finished, namely at 0 week, the total cholesterol and low-density lipoprotein contents of the model group, the drug control group, the LI05 control group and the JQI-7 golden hamsters are remarkably higher than those of the normal group, and the result indicates that a hyperlipidemia model is successfully established, after the administration is finished, namely at 8 weeks, β -diversity analysis is carried out on intestinal flora data of all groups of golden hamsters, and the obtained result is shown in table 1. from the results in table 1, compared with intestinal flora of normal groups of golden hamsters, the high-fat feed feeding can remarkably reduce the abundance of acetobacter, bifidobacterium and lactobacillus in intestinal tracts of golden hamsters, so that the abundance of bacteroides, enterococcus, escherichia and eubacterium in intestinal tracts of golden hamsters is remarkably increased, which indicates that high-fat diet can cause intestinal flora imbalance, and the abundance of other genera in intestinal flora is not remarkably different from that of the model group except eubacterium in intestinal tracts of golden hamsters, and the intestinal flora of golden hamsters can remarkably reduce the abundance of intestinal flora, so that the intestinal flora of golden hamsters can not effectively regulate the quantity of golden hamsters, the strain of golden hamsters, and can remarkably reduce the quantity of intestinal flora in intestinal flora of the intestinal tract of golden hamsters, thus the intestinal tract of golden hamsters, the intestinal tract of golden hamsters, and the intestinal tract of golden hamsters, the intestinal tract of golden hamsters, wherein the intestinal tract of golden hamsters, the intestinal tract of golden hamsters, the intestinal tract of golden hamsters, and the intestinal tract of golden hamsters, the intestinal tract of.
Table 1: relative abundance value of golden hamster on genus level in each group of golden hamster after dosing
Note: results are expressed as mean ± standard deviation (n ═ 10), and different superscript letters indicate significant differences between groups (p < 0.05).
Example 2 preparation of food and health products
In this embodiment, pediococcus pentosaceus JQI-7 is prepared into commonly used food and health products, specifically as follows:
(1) pediococcus pentosaceus fermented yoghurt
Mixing milk powder and water, homogenizing, sterilizing at 121 deg.C for 300s, cooling to 42 deg.C, inoculating activated starter: the total inoculation amount of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4 percent by weight. Fermenting at 42 deg.C for 10h, cooling, adding 1 wt% CFU109And (3) the pediococcus pentosaceus JQI-7, stirring and filling.
Wherein the milk powder is milk powder conventionally used in yogurt preparation.
(2) Pediococcus pentosaceus tablets
The formula is as follows: CFU10925% of lyophilized powder of pediococcus pentosaceus JQI-7, 60% of dietary fiber, 10% of sorbitol and 5% of magnesium stearate; the components are mixed evenly and then tabletted to prepare tablets. Wherein, the freeze-dried powder of the pediococcus pentosaceus JQI-7 is prepared by freezing, vacuumizing and drying the bacterial suspension of the pediococcus pentosaceus in an aseptic environment by a freeze dryer.
The above examples are further detailed descriptions of the present application with reference to specific embodiments, and it should not be construed that the embodiments of the present application are limited to these examples. For those skilled in the art to which the present application pertains, several simple deductions or substitutions may be made without departing from the concept of the present application, and all should be considered as belonging to the protection scope of the present application.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. The pediococcus pentosaceus is preserved in the common microorganism center of China general microbiological culture Collection center on 02/2015, and the preservation number is CGMCC No. 10511.
2. Use of pediococcus pentosaceus, deposited in the general microbiological center of the China Committee for culture Collection of microorganisms with the accession number CGMCC No.10511, on 02/2015 for 02/02, for the purpose of regulating the intestinal flora for non-diagnostic purposes.
3. Use according to claim 1 or 2, wherein said modulating the intestinal flora is performed by at least one of:
increasing the abundance of beneficial bacteria in the gut;
reducing the abundance of harmful bacteria in the intestinal tract.
4. Use according to claim 3, wherein the beneficial genera comprise at least one selected from the genera Acetobacter, Bifidobacterium, Lactobacillus.
5. The use according to claim 3, wherein the harmful genera include at least one selected from the genera Bacteroides, enterococcus, Escherichia, and Uygobacterium.
6. Use of pediococcus pentosaceus fermented cow's milk or pediococcus pentosaceus tablet for the regulation of intestinal flora for non-diagnostic purposes, the pediococcus pentosaceus fermented cow's milk or pediococcus pentosaceus tablet comprising pediococcus pentosaceus deposited at the common microorganism center of the china committee for the conservation management of microbial cultures at 2015 02 and 02, with a deposit number of CGMCC No. 10511.
7. Use according to claim 6, wherein said modulation of the intestinal flora is performed by at least one of:
the abundance of beneficial bacteria in the intestinal tract is improved,
reducing the abundance of harmful bacteria in the intestinal tract;
optionally, the beneficial genera include at least one selected from the group consisting of acetobacter, bifidobacterium, lactobacillus;
optionally, the harmful genus includes at least one selected from the group consisting of bacteroides, enterococcus, escherichia, and eurobacterium.
8. The use according to claim 6, wherein the Pediococcus pentosaceus fermented yoghurt is prepared from Pediococcus pentosaceus powder, milk powder and a leavening agent;
optionally, the starter comprises lactobacillus bulgaricus powder and lactobacillus thermophilus powder;
optionally, the content of Pediococcus pentosaceus in the Pediococcus pentosaceus powder is 1.0 × 109CFU/g；
Optionally, the total weight of the lactobacillus bulgaricus powder and the lactobacillus thermophilus powder is 0.4% based on the total weight of the pediococcus pentosaceus fermented yogurt;
optionally, the total weight of the pediococcus pentosaceus powder is 1% based on the total weight of the pediococcus pentosaceus fermented yogurt.
9. The use according to claim 6, wherein the Pediococcus pentosaceus fermented yoghurt is prepared by:
1) carrying out first mixing, homogenizing, sterilizing and first cooling treatment on the milk powder and water, wherein the sterilization is carried out for 300s at 121 ℃, and the temperature after the first cooling treatment is 42 ℃;
2) adding the activated leavening agent into the first cooling treatment product to perform fermentation treatment, wherein the fermentation treatment is performed for 10 hours at 42 ℃;
3) and carrying out second cooling treatment on the fermentation treatment product, and carrying out second mixing treatment on the second cooling treatment product and the pediococcus pentosaceus powder so as to obtain the pediococcus pentosaceus fermented yoghurt.
10. Use according to claim 6, wherein the Pediococcus pentosaceus tablet comprises: pediococcus pentosaceus lyophilized powder, dietary fiber, sorbitol, and magnesium stearate;
optionally, the content of Pediococcus pentosaceus in the Pediococcus pentosaceus freeze-dried powder is 1.0 × 109CFU/g；
Optionally, the pediococcus pentosaceus freeze-dried powder is 25 parts by weight, the dietary fiber is 60 parts by weight, the sorbitol is 10 parts by weight, and the magnesium stearate is 5 parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811196105.3A CN111035658A (en) | 2018-10-15 | 2018-10-15 | Use of pediococcus pentosaceus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811196105.3A CN111035658A (en) | 2018-10-15 | 2018-10-15 | Use of pediococcus pentosaceus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111035658A true CN111035658A (en) | 2020-04-21 |
Family
ID=70230249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811196105.3A Pending CN111035658A (en) | 2018-10-15 | 2018-10-15 | Use of pediococcus pentosaceus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111035658A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109504637A (en) * | 2018-12-29 | 2019-03-22 | 福建省农业科学院农业工程技术研究所 | One plant of Pediococcus pentosaceus and its application |
| CN110964672A (en) * | 2019-12-29 | 2020-04-07 | 江南大学 | Pediococcus pentosaceus CCFM1104, fermented food thereof and application |
| CN113388540A (en) * | 2021-05-21 | 2021-09-14 | 深圳市华大农业应用研究院 | Pediococcus pentosaceus HG-9 strain and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883995A (en) * | 2015-12-16 | 2017-06-23 | 深圳华大农业与循环经济科技有限公司 | Pediococcus acidilactici JQII-5 bacterial strains and application thereof |
| CN106883997A (en) * | 2015-12-16 | 2017-06-23 | 深圳华大农业与循环经济科技有限公司 | Pediococcus pentosaceus JQI-7 bacterial strains and its application |
| CN107099482A (en) * | 2017-06-21 | 2017-08-29 | 浙江鸣食品股份有限公司 | A kind of Pediococcus pentosaceus and its application |
| CN107693547A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of Preparation method and use of probiotic composition |
| CN107691937A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of vegetable protein beverage and preparation method thereof |
-
2018
- 2018-10-15 CN CN201811196105.3A patent/CN111035658A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883995A (en) * | 2015-12-16 | 2017-06-23 | 深圳华大农业与循环经济科技有限公司 | Pediococcus acidilactici JQII-5 bacterial strains and application thereof |
| CN106883997A (en) * | 2015-12-16 | 2017-06-23 | 深圳华大农业与循环经济科技有限公司 | Pediococcus pentosaceus JQI-7 bacterial strains and its application |
| CN107693547A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of Preparation method and use of probiotic composition |
| CN107691937A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of vegetable protein beverage and preparation method thereof |
| CN107099482A (en) * | 2017-06-21 | 2017-08-29 | 浙江鸣食品股份有限公司 | A kind of Pediococcus pentosaceus and its application |
Non-Patent Citations (2)
| Title |
|---|
| 彭灿等: "降胆固醇乳酸菌的筛选和分析比较", 《中国微生态学杂志》, vol. 29, no. 3, 31 March 2017 (2017-03-31), pages 4 - 7 * |
| 赵立平等: "微生物组学与精准医学", 上海科学技术文献出版社, pages: 252 - 253 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109504637A (en) * | 2018-12-29 | 2019-03-22 | 福建省农业科学院农业工程技术研究所 | One plant of Pediococcus pentosaceus and its application |
| CN109504637B (en) * | 2018-12-29 | 2021-10-08 | 福建省农业科学院农业工程技术研究所 | Pediococcus pentosaceus and application thereof |
| CN110964672A (en) * | 2019-12-29 | 2020-04-07 | 江南大学 | Pediococcus pentosaceus CCFM1104, fermented food thereof and application |
| CN113388540A (en) * | 2021-05-21 | 2021-09-14 | 深圳市华大农业应用研究院 | Pediococcus pentosaceus HG-9 strain and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guerra et al. | Production of four potentially probiotic lactic acid bacteria and their evaluation as feed additives for weaned piglets | |
| CN111346114A (en) | Application of lactobacillus reuteri | |
| US8440179B2 (en) | Agent for reducing visceral fat | |
| CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
| CN107354097B (en) | Lactobacillus preservative for improving survival rate of liquid lactobacillus at normal temperature and application thereof | |
| WO2022206300A1 (en) | Composition capable of facilitating defecation and use thereof | |
| US20170252381A1 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| WO2001085186A1 (en) | Preparation that contains the intestinal beneficial bacterium fermentation culture | |
| CN105942527A (en) | Probiotics and prebiotics compound preparation as well as preparation method and application thereof | |
| CN111035658A (en) | Use of pediococcus pentosaceus | |
| CN104432001A (en) | Edible composition and use thereof | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| CN102665738B (en) | Prophylactic composition for influenza infection | |
| KR101746227B1 (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
| CN115089619A (en) | Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease | |
| CN115093999A (en) | Clostridium praecox capable of improving dyslipidemia and application thereof | |
| CN113355252A (en) | Lactobacillus paracasei and application thereof | |
| US10350248B2 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN109207389B (en) | Thrombolytic lipid-lowering probiotic compound bacteria traditional Chinese medicine oral liquid and preparation method thereof | |
| CN113186118B (en) | Composite probiotic preparation for improving sow productivity and preparation method thereof | |
| CN110839693B (en) | Application of parabacteroides gibsonii in preventing or treating obesity or related diseases | |
| CN115651854A (en) | Lactobacillus plantarum YG06 strain and application thereof | |
| CN111345345A (en) | Use of pediococcus pentosaceus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |